Can we short the Morgan Stanley analyst? "4:1 risk/reward"... ? "binary outcome event having been cleared”...? Apparently it wasn't. How much do these guys get paid again? TSP------> $35---->$16 BAM? I mean none of us are perfect, but I'm not getting paid $500K+ to analyze a company. Because if I was.... .... whatever.
LVMHY had a huge earnings report and was up 5% overseas and lost the gain entirely./// Today is the day to get in.>>>>>>>>> This is super annoying Oscar Health crowing about their premium raises of which I have been a victim. Maybe there can be some revenge here as Oscar sells for all of $5- OSCR-$5.78 Gummy Of The Day Oscar Health sees FY22 premiums growth more than 80% at midpoint 16:08 OSCR Oscar Health issued 2022 guidance reflecting significant growth for its business with premiums expected to increase more than 80% YoY at the midpoint. In conjunction with guidance, the Company also announced a $305 million convertible notes transaction to strengthen the balance sheet and provide strong liquidity to support the growth of the organization. "Oscar has seen more than 70% annual premium growth, on average, over the past 5 years, demonstrating that our exceptional member experience is resonating with new and existing members alike," said Mario Schlosser, CEO and co-founder at Oscar. "We are honored to welcome our new members and serve the more than one million individuals across the country who are trusting us with their healthcare." For full year 2022, Oscar projects premiums will increase to $6.1 billion - $6.4 billion, a YoY increase of roughly 80% at the midpoint. The Company is also projecting an Adjusted EBITDA loss of ($380) million to ($480) million, which reflects both improving MLR and administrative expense ratios YoY. Finally, the Company is introducing a new key performance indicator, the Adjusted Administrative Expense Ratio, which includes insurance and technology related expenses, as well as other corporate expenses. The Company believes this additional metric provides greater visibility into its overall path to profitability.
Stoney!!!!!! I like that crazy looking painting. Speaking of premiums, I think I'm gonna put Allstate in granny's shorts. They were discussing Louis Vitton on Bloomberg earlier. I'm not buying any but I think you're right.
Mitek Systems reports Q1 adjusted EPS 22c, consensus 16c 16:11 MITK Reports Q1 revenue $32.5M, consensus $28.68M. "I am proud that the world's leading brands trust Mitek to protect their companies and their customers from growing online fraud," said CEO Max Carnecchia. "Biometrics are transforming the way we deliver authentication solutions. Our team will continue to innovate to build trust and keep people safe online." Mercury Systems awarded $17M contract for ruggedized RF microelectronics 16:24 MRCY Mercury Systems announced it was awarded a $17M contract to provide crucial RF microelectronics supporting missile capabilities of the U.S. and its allies in ensuring 21st-century air dominance. These multi-channel digital RF assemblies will help provide real-time signals intelligence data, speeding information to the warfighter. The award was received in the company's fiscal 2022 first quarter and is expected to be shipped over the next several quarters. Chewy initiated with an Outperform at RBC Capital 16:25 CHWY RBC Capital analyst Steven Shemesh initiated coverage of Chewy with an Outperform rating and $77 price target. While some share weakness in 2021 was warranted, Shemesh believes the sell-off was overdone and the risk-to-reward now skews positive, the analyst tells investors in a research note. He is bullish on Chewy's long-term to-line prospects and has conviction that supply-chain-related margin pressures are beginning to abate. Stryker should be bought at current levels, says Piper Sandler 20:55 SYK Piper Sandler analyst Matt O'Brien keeps his Overweight rating and $315 price target on Stryker after its Q4 earnings miss and below-consensus FY22 guidance. The outlook reflects the impact of COVID-19 and rising supply and labor costs, but this should not be overly surprising, and the 8% year-to-date decline in the stock price has already incorporated this view to some extent, the analyst tells investors in a research note. O'Brien adds that with Stryker's guidance "appropriately set", along with the company's strong product portfolio and the best management team in med tech, he believes that the stock should be bought at these levels. ChargePoint upgraded to Overweight from Neutral at JPMorgan 04:40 CHPT JPMorgan analyst Bill…JPMorgan upgrades ChargePoint on recent pullback in shares 07:33 CHPT JPMorgan analyst Bill Peterson upgraded ChargePoint to Overweight from Neutral with a price target of $20, down from $26. The analyst sees a good opportunity for investors following the stock's recent pullback. ChargePoint is well positioned to benefit from growth in all customer verticals in the U.S., and increasingly so in Europe, assuming resumed installations at work sites as employees gradually return to the office and additional fleet deployments that should "inflect meaningfully" this year, Peterson tells investors in a research note. Following due diligence on the electric vehicle charging sector, the analyst has developed more confidence around the ChargePoint story. https://www.youtube.com/watch?v=SuxsobINURw Stellantis provides update on China business through DPCA joint venture 05:26 STLA In 2021, Stellantis said it strengthened its business position in China laying a foundation for the company's long-term expansion. Dongfeng Peugeot Citroen Automobile, or DPCA, the joint venture formed by Stellantis and China Dongfeng Motor Corporation, sold over 100,000 vehicles in 2021, more than doubling the annual sales volume of 2020. Of the more than 100,000 vehicles, around 9,300 new energy vehicles, or NEV, were sold, which has made DPCA a net contributor of NEV and CAFC credits of Stellantis in China. The turnaround allowed significant improvement of DPCA's financial situation, setting the stage for the new DPCA strategy. Iovance Biotherapeutics upgraded to Buy from Hold at Stifel 05:51 IOVA Stifel analyst Benjamin Burnett upgraded Iovance Biotherapeutics to Buy from Hold with a price target of $25, up from $23. The analyst views the hire of Dr. Raj Puri as a "vote of confidence from someone knowledgeable of the potency assay situation." He now thinks the worst-case scenario is less likely. The two most likely scenarios that could play out from here are: Iovance announces alignment with FDA and files the Biologics License Application as expected, or the company announces there's more potency validation work needed and they push the application, Burnett tells investors in a research note. He's now more optimistic that the application is a matter of when, not if. Kirby upgraded to Buy at BTIG on improving inland barge market 06:34 KEX BTIG analyst Greg Lewis upgraded Kirby to Buy from Neutral with an $80 price target. The analyst notes that the inland barge market suffered from oversupply in 2017-2019 and then from COVID in the last two years, but it now looks ready to inflect higher. The outlook for US GDP remains constructive, which should buoy continued growth in both refined product and petrochemical volumes, Lewis further tells investors in a research note. ZoomInfo price target lowered to $60 from $85 at Mizuho 06:54 ZI Mizuho analyst Siti Panigrahi lowered the firm's price target on ZoomInfo to $60 from $85 and keeps a Buy rating on the shares. Software-as-a-service momentum has stalled thus far in 2022 amid concerns over rising interest rates, Panigrahi tells investors in a research note. However, despite the "macro-driven sell-off," the analysts does not see any deterioration of fundamentals. https://www.youtube.com/watch?v=Rr_T4Aim6Fw
You know what is so frustrating they are reporting numbers & growth over 2019 not last year so this is 40% better than best ever no comeback from Covid..... Ayyyyyyyyyy
a crazy market. this thing is dropping like 10% a day Matterport Inc 7.74 USD−0.70 (8.29%)today Jan 28, 9:45 AM EST